Director/PDMR Shareholding

RNS Number : 4613W

Redx Pharma plc

14 November 2017

 

REDX PHARMA PLC

("Redx" or "the Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

Alderley Park, November 14 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, announces that is has been notified that Iain Ross, Executive Chairman, has today acquired 348,000 Redx ordinary shares at a price of 18.036 pence per share.  Following this, Mr Ross will hold 348,000 ordinary shares in the Company, representing 0.28 per cent. of the issued share capital.

Mr Ross purchased the shares through his self-invested personal pension (SIPP) and the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Iain Ross
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification/ Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Redx Pharma plc
b)	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence ISIN: GB00BSNB6S51
b)	Nature of the transaction	Purchase of shares through self-invested personal pension (SIPP)
c)	Price(s) and volume(s)	348,000 ordinary shares at a price of 18.036 pence per share
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	14 November 2017
f)	Place of the transaction	London Stock Exchange, AIM (XLON)

For further information, please contact:

Redx Pharma Plc	T: [phone]
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated Advisor & Broker)	T: [phone]
Phil Davies
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting	T: [phone]
Simon Conway/Stephanie Cuthbert

About Redx Pharma Plc

Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of oncology and fibrosis that address significant unmet medical need. Redx has a significant in-house discovery team with proven world-class chemistry capabilities.

 

END

 

 

DSHUSUARBVAAAAA